Primary sclerosing cholangitis

Majoie, Charles B; Reeders, Jacques W. A. J.

doi:10.1007/s002619900171

Search citation statements

Order By: Relevance

Paper Sections

Select...

Guest Discussant's Reply1

Original Article1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1999

2007

Publication Types

Select...

Article7

Relationship

Self Cite0

Independent7

Authors

Journals

Cited by 7 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of greater concern is the possibility of bile-duct neoplasm accounting for the radiographic changes. Although PSC is typically ascribed to cholangiocarcinoma, other cancers mimic the radiographic appearances of PSC [9]. Furthermore, as described above, I am already confi-…”

Section: Guest Discussant's Replymentioning

confidence: 83%

Recurrent Cholangitis Following “Successful” Treatment for Gallbladder Cancer

Enns

Baillie²

2001

Endoscopy

View full text Add to dashboard Cite

Section: Guest Discussant's Replymentioning

confidence: 83%

Recurrent Cholangitis Following “Successful” Treatment for Gallbladder Cancer

Enns

Baillie²

2001

Endoscopy

View full text Add to dashboard Cite

“…©2003 Pulsus Group Inc. All rights reserved P rimary sclerosing cholangitis (PSC) is a chronic, progressive, fibrosing condition of unknown etiology affecting the intrahepatic and extrahepatic bile ducts, and frequently culminating in secondary biliary cirrhosis (1)(2)(3)(4). Despite the numerous medical and surgical therapies that have been tried, ursodeoxycholic acid and liver transplantation remain the mainstays of therapy in select patients (5)(6)(7)(8)(9)(10)(11)(12)(13)(14).…”

Section: Original Articlementioning

confidence: 99%

Predictors of Successful Clinical and Laboratory Outcomes in Patients with Primary Sclerosing Cholangitis Undergoing Endoscopic Retrograde Cholangiopancreatography

Enns

Mergener

et al. 2003

Canadian Journal of Gastroenterology

View full text Add to dashboard Cite

First, in PSC, clinical and laboratory improvement is more common in patients undergoing therapeutic ERCP than diagnostic ERCP. Second, aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase improve following both diagnostic and therapeutic ERCP, and should therefore not be relied upon to determine the success of the procedure. Third, bilirubin levels decreased in the therapeutic group but remained unchanged in the diagnostic group, suggesting that the serum bilirubin level may be a more sensitive indicator of successful therapeutic intervention than transaminases. Fourth, common bile duct strictures, dominant strictures and bilirubin levels are important variables in determining the success of an ERCP in PSC. Finally, complication rates after therapeutic ERCP are similar to those after diagnostic ERCP in PSC patients. However, severe complications occur more commonly in the therapeutic group.

show abstract